Idorsia and Mochida enter into a license agreement for the supply, co-development and co-marketing of daridorexant in Japan
(WorldNews Switzerland)

Allschwil, Switzerland - December 5, 2019 Idorsia Ltd (SIX: IDIA) and Mochida Pharmaceutical Co., Ltd. today announced that they have entered into an exclusive license agreement for the supply, co-development and co-marketing of daridorexant, Idorsia`s dual orexin receptor antagonist (DORA), for insomnia and related disorders in Japan. Idorsia will receive an initial payment of 1 billion Japanese yen (approximately 9 million Swiss francs) and will be entitled to three additional development and regulatory milestones. Idorsia will also be entitled to sales milestones and tiered royalty payments based on net sales achieved by Mochida. Costs associated with the co-development of daridorexant...